The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here is one stock where Wall Street’s excitement appears well-founded and two where analysts may be overlooking some important risks.

Two Stocks to Sell:

Omnicell (OMCL)

Consensus Price Target: $54.14 (64.9% implied return)

Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ: OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.

Why Do We Think OMCL Will Underperform?

1. Sales tumbled by 7.4% annually over the last two years, showing market trends are working against its favor during this cycle
2. Earnings per share fell by 9.6% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
3. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

Omnicell’s stock price of $30.76 implies a valuation ratio of 17.2x forward price-to-earnings. Check out our free in-depth research report to learn more about why OMCL doesn’t pass our bar.

ANI Pharmaceuticals (ANIP)

Consensus Price Target: $78.67 (17.3% implied return)

With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.

Why Does ANIP Fall Short?

1. Smaller revenue base of $614.4 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
2. Performance over the past five years was negatively impacted by new share issuances as its earnings per share were flat while its revenue grew
3. Negative returns on capital show management lost money while trying to expand the business

At $69.82 per share, ANI Pharmaceuticals trades at 13.2x forward price-to-earnings. To fully understand why you should be careful with ANIP, check out our full research report (it’s free).

One Stock to Buy:

Tecnoglass (TGLS)

Consensus Price Target: $89.67 (16.2% implied return)

The first-ever Colombian company to trade on the NASDAQ, Tecnoglass (NYSE: TGLS) is a manufacturer of architectural glass, windows, and aluminum products.

Why Do We Love TGLS?

1. Annual revenue growth of 15.6% over the last five years was superb and indicates its market share increased during this cycle
2. Excellent operating margin of 27% highlights the efficiency of its business model, and its profits increased over the last five years as it scaled
3. Earnings per share have massively outperformed its peers over the last five years, increasing by 39.8% annually

Tecnoglass is trading at $72 per share, or 17x forward price-to-earnings. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.

Stocks We Like Even More

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.

Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free.